www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

Global EditionASIA 中文雙語Fran?ais
Opinion
Home / Opinion / Featured Contributors

How moneyed interests spawned and sustained US opioid crisis

By Xu Ying | chinadaily.com.cn | Updated: 2023-10-16 10:31
Share
Share - WeChat
Cai Meng | China Daily

The opioid epidemic ravaging communities across America represents a profound public health crisis and moral failing decades in the making. This unfolding tragedy spotlights how profit motives and regulatory lapses incubated a contagion of addiction that enriched drug makers while extracting a ghastly human toll. Behind the statistics lie broken lives and betrayed trust.

The sheer scale of opioid mortality remains shocking despite growing awareness and mitigation efforts. With over 100,000 deaths in 2021 alone, opioid overdoses claimed more American lives yearly than car crashes or gun violence. And the crisis is worsening, with synthetic opioids like fentanyl causing record spikes in fatalities by permeating illicit drug supplies. This exponential loss of life now exceeds the darkest years of the AIDS epidemic.

Rather than a public health disaster happening organically, the opioid crisis was manufactured through calculated choices to drive addiction for profit. The relentless promotion of OxyContin as a low-risk analgesic directly seeded today's landscape littered with fatalities. Despite knowing the enormous dependency risks, the Sackler family deployed false marketing to push their blockbuster pill, raking in over $35 billion from Oxy sales since the 1990s.

The medical establishment shares culpability for becoming complicit conduits enabling mass over-prescription. Professional associations funded by opioid makers popularized the myth that doctors were under-treating chronic pain, abandoning caution about addictive risks. Misleading assertions that dependency was rare if opioids were properly prescribed for pain became common, despite contrary evidence. With incentives skewed, restraint was abandoned as doctors followed loosened guidelines.

Lax oversight from captured regulators like the FDA and DEA also facilitated the pharmaceutical free-for-all. Despite clear warnings about addiction and diversion, agencies succumbed to fierce industry lobbying to permit aggressive opioid marketing and distribution. Their regulatory surrender allowed and even abetted the ensuing epidemic rather than blocking it. This abdication of duty left Americans unprotected.

With profit seeking unconstrained and oversight neutered, conditions ripened for catastrophe on a national scale. The result after two decades was a historic public health crisis claiming over one million American lives, exceeding Vietnam War casualties. This colossal policy failure has rightly been labelled a "national disgrace" by reform advocates across the political spectrum.

Revelations of calculated choices sparking this crisis spotlight the corrosive influence of moneyed interests on governing institutions. The opioid epidemic illustrates how profit motives can capture regulators and corrupt policy to enrich a privileged few at monstrous public expense. The outsized lobbying power of opioid makers won them effective impunity while stifling reforms, allowing intended consequences to unfold.

Industry players secured enablers at the highest levels through strategic donations to politicians, advocacy groups, and regulators seeking influence. Opiate makers like Purdue lavished millions on contributions and lobbying funds to shape policy responses amenable to their bottom lines. Many lawmakers pursuing opioid deregulation were themselves among the biggest recipients of pharma cash, raising conflict of interest questions.

The notorious "revolving door" between regulators and regulated further entwined public agencies with opioid corporate interests. Several senior DEA officials involved in drug policy oversight have since joined opioid makers they once regulated, or defend them as lobbyists.

Such relationships inevitably raise doubts over whose interests the governing institutions truly serve under the capture of moneyed influences. Does the inordinate access and power of corporate lobbies undermine regulatory missions by corrupting public servants into servants of industry? Have democratic ideals of responsive leadership devolved into a system rigged by elite influence networks and tycoons? The tragic arc of the opioid crisis lends credence to critiques of America as a plutocracy masquerading as a republic.

As the opioid catastrophe escalated, responses from political leaders long paid to ignore warning signs ranged from tepid to complicit. Despite constituencies being decimated, many avoided policies that could curb profits, like prosecuting company leaders or funding treatment. Belated emergency decrees provided cover while avoiding real accountability. Opioid makers still reap billions in profits after paying settlements trivial relative to the scale of harms inflicted.

This sordid history raises skepticism about entrusting crisis response solely to the perpetrators and enablers who incubated the epidemic. Their pledges to make amends now ring hollow absent owning responsibility. Meaningful reforms appear necessary to constrain corporate power and corrupt elite influence that subordinate public welfare to private interests. Americans shaken by this nightmarish episode may conclude the institutions are too compromised to self-correct and must be redeemed through progress over plutocracy.

The merciless human toll of America's opioid plague spotlights endemic corruption of governing systems by moneyed special interests. This ongoing public health disaster was spawned by the callous pursuit of profit, enabled by regulatory surrender in the face of lobbying might. The scheme engorged the coffers of opioid makers while crushing families, communities, and faith in leaders. Its immense costs lay bare the moral bankruptcy of institutions serving the privileged few at such grievous public expense.

Redeeming civic promise requires truth, justice and change. The powerful must be held to account, balance restored to governance, and public interest reinstalled over private enrichment. For generations, the opioid crisis will be remembered as either the nadir spurring renewal, or another chapter of eroding trust as elites escape consequences. Its lessons must shape the necessary reckoning ahead to reclaim democracy from moneyed interests and reaffirm that all lives matter over lobbyists. In such a colossal crisis and tragedy, any attempt to shift blame onto others is an unforgivable crime of deceiving the American people.

The author is a Beijing-based commentator. The views don't necessarily reflect those of China Daily.

If you have a specific expertise, or would like to share your thought about our stories, then send us your writings at opinion@chinadaily.com.cn or comment@chinadaily.com.cn.

 

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 欧美h版成版在线观看 | 91久久国产成人免费观看资源 | 欧美久久久久 | 最刺激黄a大片免费观看下截 | 日本一区深夜影院深a | 欧美888| a级国产乱理伦片在线观看99 | 国产免费一区二区三区在线 | 欧美一级视频在线 | 国产一久久香蕉国产线看观看 | 亚洲欧美日韩专区 | 亚洲男人在线 | 国产真实乱子伦精品视 | 一区二区精品在线观看 | 嫩草一区二区三区四区乱码 | 亚洲一区二区三区精品视频 | 亚洲精品成人av在线 | 色悠久久久久综合网伊人男男 | 极品精品国产超清自在线观看 | 欧美三级视频在线观看 | 老妇综合久久香蕉蜜桃 | 亚洲视频综合网 | 女人张开腿让男人桶免费最新 | 国产成人一区二区三区在线视频 | 精品国产免费人成在线观看 | 久久99精品久久久久久国产越南 | 日韩欧美中文字幕一区二区三区 | 操美女大逼视频 | 国产99高清一区二区 | 国产亚洲欧美日韩在线观看一区二区 | 国产精品黄页网站在线播放免费 | 欧美黑人巨大最猛性xxxxx | 国产成人精品三区 | 成人欧美网站免费 | 狠狠色丁香婷婷久久综合不卡 | 亚洲成a人片在线观看 欧美 | 国产精品hd在线播放 | 日韩三级视频 | 日本一区二区三区高清福利视频 | 91精品国产欧美一区二区 | 欧洲成人免费视频 |